Patients with evidence of active bleeding or bleeding diathesis will be excluded (Note: patients aged > 17 years with excess of 2.5 mL of hemoptysis are not eligible)
Patients with an active, bleeding diathesis
Patients with a history of bleeding diathesis are ineligible
History of bleeding diathesis or clinically significant bleeding within 14 days prior to randomization.
History of hemolytic anemia or bleeding diathesis
Patients with an active, bleeding diathesis
Known hemorrhagic diathesis or active bleeding disorder
Subjects may not have a history of bleeding diathesis or abnormal sensitivity to ionizing radiation
Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
Recent or active bleeding diathesis or arterial vascular event within 4 weeks
Patients with an active bleeding diathesis
If they have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
Requires therapeutic anticoagulation or has known active bleeding diathesis
Active uncontrolled bleeding or a known bleeding diathesis
Contraindication for ibrutinib use because of a bleeding diathesis.
Evidence of a bleeding diathesis.
History of bleeding diathesis
Active uncontrolled bleeding or a known bleeding diathesis
Any evidence of bleeding diathesis (patients on therapeutic warfarin or heparin will be excluded)
Evidence of active bleeding or bleeding diathesis
Known history of bleeding diathesis
Evidence or history of bleeding diathesis
Patients with an active bleeding diathesis
Patients with an active bleeding diathesis
Patient on anticoagulation or with bleeding diathesis due to risk of hematomas at injection site
Patients with evidence of bleeding diathesis are not eligible
For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy which cannot be interrupted for biopsy
Any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
Evidence or history of bleeding diathesis
Must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
Patients must not have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
History of bleeding disorder or diathesis
Presence of bleeding diathesis
Evidence of active bleeding or bleeding diathesis
No active uncontrolled bleeding/bleeding diathesis
Active bleeding diathesis or history of major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within the past 6 months
Evidence of active bleeding or bleeding diathesis
Evidence of uncontrollable bleeding diathesis
Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
Evidence of active bleeding or bleeding diathesis
Patients with an active bleeding diathesis
Bleeding diathesis, not correctable by usual forms of therapy
Bleeding diathesis, not correctable by usual forms of therapy
Active uncontrolled bleeding or a known bleeding diathesis
Haemorrhagic diathesis (i.e. haemophilia)
If they have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
Active uncontrolled bleeding or a known bleeding diathesis
Patients with an active, bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Subjects with known bleeding diathesis will be excluded from the study.
Patients with history of bleeding diathesis are ineligible
Subjects with history of bleeding diathesis
Patients with evidence of active bleeding or bleeding diathesis will be excluded (patients with excess of 2.5 mL of hemoptysis are not eligible)
Evidence of bleeding diathesis
Patients with evidence of active bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Known hemorrhagic diathesis or active bleeding disorder
Active bleeding diathesis or history of any major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within 6 months of enrollment
History of bleeding diathesis.
Known history of a bleeding diathesis.
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of bleeding diathesis
History of congenital bleeding diathesis
Active bleeding diathesis
Patients with history of bleeding diathesis
History of hemolytic anemia or bleeding diathesis
In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections
Evidence of history of bleeding diathesis.
Active bleeding diathesis
Significant history of bleeding events or pre-existing bleeding diathesis =< 6 months of randomization (unless the source of bleeding has been resected)
Patients with active bleeding diathesis
Patients with evidence or history of any bleeding diathesis, irrespective of severity
Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
Patients with evidence of a bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Any active uncontrolled bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
History of bleeding diathesis
Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
Evidence of active bleeding or bleeding diathesis
History of bleeding diathesis or extensive bleeding requiring blood transfusion within 14 days of enrollment
Patient must not have evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Patients with an active, bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Significant history of bleeding events or pre-existing bleeding diathesis, within 6 months of randomization (unless the source of bleeding has been resected)
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
EXPANSION COHORT ONLY: Evidence of active bleeding or bleeding diathesis
Known bleeding diathesis
Patients must not have any evidence of bleeding diathesis
Patients taking anticoagulants or with a history of a bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis; any medical condition requiring systemic anticoagulation (including anti-platelet agents)
Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.
Evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement
Evidence of active bleeding or bleeding diathesis.
Patients with an active, bleeding diathesis
Known bleeding diathesis or hemophilia
Known bleeding diathesis Known history of hereditary hemorrhagic telangiectasia (HHT).
Active, bleeding diathesis.
Known bleeding diathesis.
For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy.
No history of bleeding diathesis.
Patients with an active, bleeding diathesis
History of bleeding diathesis
Evidence of active bleeding or bleeding diathesis.
No bleeding diathesis
Patients must not have any evidence of bleeding diathesis or signs of active bleeding
History of bleeding diathesis
Known bleeding diathesis
Patients with evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement
Patients with an active, bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Bleeding diathesis, resulting in symptomatic bleeding.
Evidence of active bleeding or bleeding diathesis
No known bleeding diathesis
Known bleeding or thrombotic diathesis
Bleeding diathesis or inability to hold anticoagulation for surgery
Has known bleeding diathesis that would be a safety risk;
Active bleeding diathesis
Non-correctable bleeding diathesis
Familial bleeding diathesis
Known bleeding diathesis
History of a bleeding diathesis or current anticoagulant therapy
Bleeding diathesis
active, bleeding diathesis;
Patients with or with a history of uncontrolled bleeding diathesis
No history of bleeding diathesis
Patient must not have evidence of active bleeding or bleeding diathesis
Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
